Abstract: The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medications are grouped together on a per dose basis in a plurality of blister pack recesses. A single cover sheet is used to commonly seal the related medications to be used together, such that when the corresponding cover sheet is removed the multiple medications are commonly accessed.

Abstract: Techniques for ensuring acceptability of legal agreements entered into as part of a computer-facilitated workflow, e.g., for accepting a license agreement while installing software on a computer system owned by an organization. If the license has an approved status in an agreements database, the user can accept the license agreement during the software install process. If the license has a disapproved status in the agreements database, the user then rejects the license agreement during the software install process (or an install mechanism may simply aborts installation of the software). The process for other computer-facilitated workflows is similar.

Abstract: Methods and pharmaceutical compositions for protecting pharmaceutical compounds (or drugs) in acidic environments are provided. Methods of treatment using formulations capable of protecting pharmaceutical compounds in acidic environments are also provided. Formulations provided generally comprise a therapeutically effective amount of at least one pharmaceutical compound, and a pharmaceutically acceptable protectant. The pharmaceutically acceptable protectant of the invention generally comprises a water-soluble acid neutralizer, and a water-insoluble acid neutralizer.

Abstract: A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate.

Abstract: A computer-implemented method for managing maintenance of computer program can include the steps of receiving usage data from a plurality of users of the computer program, wherein the usage data identifies at least one portion of the computer program accessed by one of the users, and for each portion of the computer program, determining a usage according the received usage data and assigning a priority level according to the determined usage, where the priority level indicates a relative priority of the portion compared to other portions in the computer program.

Abstract: Systems, methods and devices for using ephemeris data in GNSS receivers and systems are provided. Receivers using synthetic ephemeris data for longer ephemeris availability under poor reception conditions are updated using a variety of techniques that allow for the transfer of accurate information onto degraded synthetic ephemeris information.

Abstract: Provided herein is a pharmaceutically acceptable composition comprising a biguanide containing antimicrobial agent and an additional antimicrobial agent. The invention further comprises topically administering the pharmaceutically acceptable composition to a patient in need of treatment.

Abstract: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

Abstract: The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

Abstract: The present invention provides methods for developing conifer cotyledonary somatic embryos. In some embodiments, the methods of the invention include the step of culturing conifer pre-cotyledonary somatic embryos on a porous membrane, that is at least intermittently contacted with liquid development medium, for a period of time sufficient to produce conifer, cotyledonary, somatic embryos from the pre-cotyledonary somatic embryos.

Abstract: The present invention provides methods for developing conifer cotyledonary somatic embryos. In some embodiments, the methods of the invention include the step of culturing conifer pre-cotyledonary somatic embryos on a porous membrane, that is at least intermittently contacted with liquid development medium, for a period of time sufficient to produce conifer, cotyledonary, somatic embryos from the pre-cotyledonary somatic embryos.

Abstract: A pharmaceutical combination for minimizing pharmacokinetic drug-drug interaction is described including a first pharmaceutical component having a particular pharmacokinetic profile in a mammal and a second pharmaceutical component formulated for parenteral administration having an altered pharmacokinetic profile different from the unaltered pharmacokinetic profile of the second pharmaceutical component, which would interfere with the pharmacokinetic profile of the first pharmaceutical component. Due to its altered pharmacokinetic profile, the second pharmaceutical component does not substantially affect the pharmacokinetic profile of the first pharmaceutical component.

Abstract: The invention provides new double metal cyanide (DMC) catalysts for preparing polyetherpolyols by the polyaddition of alkylene oxides to starter compounds which contain active hydrogen atoms, wherein the catalyst comprises a) double metal cyanide compounds, b) bile acids or their salts, esters or amides and c) organic complex ligands. The catalysts according to the invention show greatly increased activity during preparation of a polyetherpolyol.

Abstract: The present invention provides methods for producing conifer cotyledonary somatic embryos. The methods of the present invention each includes the step of culturing embryogenic conifer tissue in, or on, a development medium for a period of time sufficient to produce conifer cotyledonary somatic embryos from the embryogenic conifer tissue, wherein the volume of development medium is in the range of from about 35 ml to about 50 ml per 0.5 mL of embryogenic conifer tissue.

Abstract: The present invention provides methods for multiplying conifer embryogenic tissue. The methods of the present invention each include the step of continuously culturing conifer embryogenic tissue in liquid multiplication medium for a period of time sufficient for the embryogenic tissue to multiply.

Abstract: In order to allow application of any coating under a vacuum over a volatile gelatinous layer, such as polymer dispersed liquid crystal (PDLC) on an optical glass substrate with a transparent electrode, such as indium tin oxide (ITO) on its surface, a layer of an intermediate stress absorbing polymeric material is first applied to cover the volatile gelatinous layer to prevent evaporation and escape of volatiles, thereafter the coating is applied under a very high vacuum using for example a technique called Physical Vapor Deposition (PVD) or sputtering.

Abstract: A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin ?-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

Abstract: In order to allow application of any coating under a vacuum over a volatile gelatinous layer, such as polymer dispersed liquid crystal (PDLC) on an optical glass substrate with a transparent electrode, such as indium tin oxide (ITO) on its surface, a layer of an intermediate stress absorbing polymeric material is first applied to cover the volatile gelatinous layer to prevent evaporation and escape of volatiles, thereafter the coating is applied under a very high vacuum using for example a technique called Physical Vapor Deposition (PVD) or sputtering.

Abstract: The invention relates to novel double metal cyanide (DMC) catalysts for the preparation of polyether polyols by polyaddition of alkylene oxides to starter compounds containing active hydrogen atoms, wherein the catalyst contains a) double metal cyanide compounds, b) organic complex ligands other than c), and c) complex ligands formed by introduction of a glycidyl ether into the catalyst. The catalysts according to the invention have greatly increased activity in the preparation of polyether polyols.

Abstract: Flexible polyurethane foams are produced from a polyisocyanate and a polyether polyol which has been alkoxylated in the presence of a double metal cyanide catalyst and that has at least one ethylene oxide-propylene oxide mixed block.